Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis

Phase 4 Completed NCT03963375

Summary

The purpose of this study is to better understand the mechanism of action (MoA) of cladribine tablets by exploring the effect on central nervous system (CNS) and blood biomarkers relevant in the relapsing forms of multiple sclerosis (RMS; to include relapsing-remitting MS \[RRMS\] or active secondary progressive MS).

Change in CD3+ T Cells % From Baseline to Week 5

Baseline to Week 5 (5 weeks after first cladribine dose) · Percentage of CD3+ T cells

Change in CD3+ T Cells % From Baseline to Week 10

Baseline to Week 10 (10 weeks after first cladribine dose) · Percentage of CD3+ T cells

Change in CD3+ T Cells % From Baseline to Year 1

Baseline to Year 1 (45 weeks after first cladribine dose) · Percentage of CD3+ T cells

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

• A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of — Mapi Pharma Ltd.
• A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patient — Genzyme, a Sanofi Company
• A Study of Oxidative Pathways in MS Fatigue — University of California, San Francisco
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocr — Hoffmann-La Roche
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocr — Hoffmann-La Roche
• Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral — Shionogi

All trials